Skip to main content

Nasal Polyps News

Related terms: Polyps, Nasal

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

South San Francisco, CA – April 12, 2021 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...

Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps

South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...

FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis...

Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced...

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps

YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 – Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Hay Fever, Allergic Rhinitis

Related drug support groups

Xolair, omalizumab